Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy
Explore this paper's citation graph
Summary
The GC predicted BF and metastasis after post-RP irradiation in men receiving radiation therapy (RT) after radical prostatectomy and may be useful for improved decision-making for treatment of high-risk prostate cancer.
- Type
- article
- Published
- 2014-07-08
- Cited by
- 166
- References
- 36
- Access
- Open access
- OpenAlex
- https://openalex.org/W25035207
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:6279674
Keywords
Computer science
References
- Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death
- Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group
- Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
- Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population
- Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines.
- Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
- A single-sample microarray normalization method to facilitate personalized-medicine workflows
- Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features
- Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates.
- REporting recommendations for tumour MARKer prognostic studies (REMARK)
- A Proportional Hazards Model for the Subdistribution of a Competing Risk
- Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
- The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy
- Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
- Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
- Exon array data analysis using Affymetrix power tools and R statistical software
- Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design
Cited by
- High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer
- Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies
- Cost‐effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer
- Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence
- RNA Biomarkers to Facilitate the Identification of Aggressive Prostate Cancer
- What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
- Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer
- Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
- Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery
- Characterization of 1,577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathological Insights into Molecular Subtypes
- Molecular Profiles of Prostate Cancer: To Treat or Not to Treat.
- Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
- A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
- Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence
- Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes?
- A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy
- Evaluating the Clinical Impact of a Genomic Classifier in Prostate Cancer Using Individualized Decision Analysis
- Adjuvant radiation for node-positive disease after prostatectomy: more good news, but who will listen?
- Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
- Evolving transcriptomic fingerprint based on genome‐wide data as prognostic tools in prostate cancer
Related papers
No related papers recorded.